Enliven Therapeutics prices upsized public offering at $37.5 per share, targets $400 million gross proceeds
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. ELVN | 0.00 |
- Enliven Therapeutics priced an upsized underwritten public offering of 8,933,334 common shares at USD 37.5 per share.
- Offering also includes pre-funded warrants for up to 1,733,333 shares at USD 37.499 each, with a USD 0.001 exercise price.
- Gross proceeds expected at about USD 400 million, before underwriting discounts and offering expenses.
- Closing expected on or about June 15, 2026, subject to customary conditions.
- Underwriters have a 30-day option to buy up to 1,600,000 additional common shares at the offering price, less discounts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606112239PR_NEWS_USPR_____LA82310) on June 12, 2026, and is solely responsible for the information contained therein.